Interleukin-6 upregulates paraoxonase 1 gene expression via an AKT/NF-κB-dependent pathway

Biochemical and Biophysical Research Communications

Volumn 437, Issue 1, 2013, Pages 55-61

  Cheng, Chi Chih ^a   Hsueh, Chi Mei ^b   Chen, Chiu Yuan ^c   Chen, Tzu Hsiu ^d   Hsu, Shih Lan ^a,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NANHUA UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^e NATIONAL CHI NAN UNIVERSITY   (Taiwan)

Author keywords

AKT; Atherosclerosis; Interleukin 6; NF B; Paraoxonase 1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ARYLDIALKYLPHOSPHATASE 1; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEIN KINASE B;

ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION;

AKT; ATHEROSCLEROSIS; INTERLEUKIN-6; NF-ΚB; PARAOXONASE 1;

ARYLDIALKYLPHOSPHATASE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84880508065     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.034     Document Type: Article

References (24)

1. Mackness M., Durrington P., Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr. Opin. Lipidol. 2004, 15:399-404.
2. Rochu D., Chabriere E., Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007, 233:47-59.
3. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 2005, 69:541-550.
4. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
5. Mackness B., Mackness M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv. Exp. Med. Biol. 2010, 660:143-151.
6. Lagrand W.K., Visser C.A., Hermens W.T., Niessen H.W., Verheugt F.W., Wolbink G.J., Hack C.E. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999, 100:96-102.
7. Feingold K.R., Memon R.A., Moser A.H., Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139:307-315.
8. Kumon Y., Nakauchi Y., Suehiro T., Shiinoki T., Tanimoto N., Inoue M., Nakamura T., Hashimoto K., Sipe J.D. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 2002, 9:160-164.
9. Van Lenten B.J., Wagner A.C., Navab M., Fogelman A.M. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J. Biol. Chem. 2001, 276:1923-1929.
10. Kumon Y., Suehiro T., Ikeda Y., Hashimoto K. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci. 2003, 73:2807-2815.
11. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
12. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
13. Cahill C.M., Rogers J.T. Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J. Biol. Chem. 2008, 283:25900-25912.
14. Wang L., Walia B., Evans J., Gewirtz A.T., Merlin D., Sitaraman S.V. IL-6 induces NF-kappa B activation in the intestinal epithelia. J. Immunol. 2003, 171:3194-3201.
15. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 2006, 86:515-581.
16. Bansal M.B., Kovalovich K., Gupta R., Li W., Agarwal A., Radbill B., Alvarez C.E., Safadi R., Fiel M.I., Friedman S.L., Taub R.A. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J. Hepatol. 2005, 42:548-556.
17. Hojo H., Kasakura T., Zuinen R., Aoki M., Yamaguchi M., Chikuma T., Sato M. Production of interleukin-6 and its implication in rats after subcutaneous injection of carbon tetrachloride. J. Health Sci. 2002, 134-139.
18. Marsillach J., Camps J., Ferre N., Beltran R., Rull A., Mackness B., Mackness M., Joven J. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol. 2009, 9:3.
19. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2002, 2:725-734.
20. Cheng C.C., Wu L.C., Lai J.M., Chen C.T., Hsueh C.M., Hsu S.L. Ethanol extract of Graptopetalum paraguayense upregulates paraoxonase 1 gene expression via an AKT/NF-kappaB-dependent pathway. Am. J. Chin. Med. 2012, 40:357-372.
21. Fry M.J. Structure, regulation and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta 1994, 1226:237-268.
22. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401:82-85.
23. Madrid L.V., Mayo M.W., Reuther J.Y., Baldwin A.S. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 2001, 276:18934-18940.
24. Shiner M., Fuhrman B., Aviram M. Macrophage paraoxonase 2 (PON2) expression is upregulated by unesterified cholesterol through activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Biol. Chem. 2007, 388:1353-1358.